AraC: up for down

detailed results are shown for 4 of them, specifically, compounds 5, 6, 7, and 8. Using a kinome assay, the authors show that PROTAC modification leads to loss of tight specificity for ruxolitinib and baricitinib, which are normally JAK1/JAK2 specific.In addition to the 4 JAKs, PROTACs gained specificity for YSK4, MAP3K2, and MAP3K3 and other kinases.